Accretion Pharmaceuticals Limited — Investor Meet, 22-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Accretion Pharma, listed May 2025, reported robust H1 FY26 results. Net revenue surged 135.59% YoY to INR 43.74 Cr, with PAT up 92.81% to INR 4.75 Cr. EBITDA margin was 16.17%. Growth stemmed from IPO-funded capacity expansion (40% increase) and diversified product mix. The company secured Malawi cGMP approval, opening direct exports, and is pursuing 100+ product registrations in new markets like Philippines and Ghana. Management expects sustained strong revenue momentum and aims for 20-22% EBITDA margins, with current investments in registrations impacting short-term margins. Outlook is positive, driven by a strong order book and expanding global presence.